Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Endothelial Progenitor Cells in Umbilical Cord Blood in Preeclampsia and IUGR

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2008 by Medical University of South Carolina.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT00634855
First received: February 19, 2008
Last updated: March 12, 2008
Last verified: March 2008
  Purpose

The objective of this study is to determine whether there are alterations in the population of endothelial progenitor cells in umbilical cord blood samples of infants born in the setting of maternal preeclampsia or fetal growth restriction.


Condition
Preeclampsia
IUGR

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Endothelial Progenitor Cells in Umbilical Cord Blood in Preeclampsia and IUGR

Resource links provided by NLM:


Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • Proportions of endothelial progenitor cells present in umbilical cord [ Time Frame: After birth ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples With DNA

Whole blood


Estimated Enrollment: 30
Study Start Date: March 2008
Groups/Cohorts
Complicated
Women with pregnancies complicated by intrauterine growth restriction or preeclampsia
Normal
Women with normal pregnancies

Detailed Description:

Preeclampsia remains a significant cause of neonatal and maternal morbidity and mortality. This disorder is found in 5-7% of pregnancies and its incidence is increased in gravid patients with multiple gestations, chronic hypertension, renal disease, autoimmune disease, and at extremes of maternal age. It is responsible for 15% of preterm births which is accompanied by a resultant increase in neonatal morbidity and mortality. In developing countries, it is responsible for approximately 50,000 maternal deaths each year. No widespread intervention to prevent this disease has been found effective and the only effective treatment remains delivery of the fetus.

To date, the cause of preeclampsia is not known although many agree that preeclampsia is a two-stage disease as described by Roberts et al. with the placenta of central importance. The first stage involves poor placental perfusion usually a result of impaired vascular remodeling in early pregnancy or from maternal disease. This leads to the second stage, which is the maternal syndrome of preeclampsia and involves both endothelial and leukocyte activation.

Preeclampsia is associated with an increased maternal cardiovascular risk later in life. Women with a history of preeclampsia demonstrate altered expression of angiogenesis-related proteins and increased insulin resistance as measured by the homeostasis model of insulin resistance. Additionally, preeclampsia is associated with an increase in future cardiovascular risk in the fetus.

Endothelial dysfunction and abnormal regulation of vascular tone that is present in preeclampsia suggests abnormal development of vascular cells such as endothelial progenitor cells. The increased cardiovascular risk of neonates born in the setting of IUGR and preeclampsia also suggests the possibility of abnormal development of endothelial progenitor cells in the fetal compartment in these disease states. The purpose of this pilot project is to determine the effects of preeclampsia/IUGR on endothelial progenitor cells derived from fresh umbilical cord blood.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Pregnant women who are between 30 and 40 weeks gestation and are admitted to MUSC.

Criteria

Inclusion Criteria:

  • Pregnant women 18-45
  • Gestational age between 30-40 weeks plus:

    • Uncomplicated pregnancy or
    • Fetal estimated weight <10% for gestational age or abdominal circumference <5% or
    • Preeclampsia by ACOG criteria:

      1. HTN > 140/90 on two occasions
      2. Proteinuria > 300mg on 24 hour urine specimen or 1+ on urine dip

Exclusion Criteria:

  • Non-reassuring fetal status
  • Congenital abnormalities
  • Multiple gestations
  • Clinical Chorioamnionitis
  • Recent infectious disease (within 2 weeks)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00634855

Contacts
Contact: Ashley Ryan, MD 8437924500 ryanas@musc.edu
Contact: Eugene Chang, MD 8437924500 changey@musc.edu

Locations
United States, South Carolina
Medical University of South Carolina Not yet recruiting
Charleston, South Carolina, United States, 29425
Principal Investigator: Ashley Ryan, MD         
Sponsors and Collaborators
Medical University of South Carolina
Investigators
Principal Investigator: Ashley Ryan, MD Medical University of South Carolina
  More Information

No publications provided

Responsible Party: Ashley Ryan, MD, Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT00634855     History of Changes
Other Study ID Numbers: HR # 17821
Study First Received: February 19, 2008
Last Updated: March 12, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Medical University of South Carolina:
Endothelial progenitor cells
Endothelial dysfunction

Additional relevant MeSH terms:
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications

ClinicalTrials.gov processed this record on November 20, 2014